Gagliano-Jucá et al. 2017 [35] |
RCT: Testosterone replacement
therapy effect on QTc |
18 - 64 years old men |
235 |
ECG parameters:
QTcF |
Treatment with testosterone: QTc shortening, hERG (G)
upregulation and ICaL (IC) inhibition. |
Gagliano-Jucá et al. 2018 [36] |
Prospective cohort study: Changes
in QT with ADT (control: prostatectomy no ADT treatment) |
59 - 75 years
old men |
71 |
QT length |
Treatment with testosterone: QT shortening,
hERG (G) upregulation and ICaL (IC)
inhibition. |
Huo et al. 2019 [37] |
Experimental study: Study sex hormonal
influences on human iPSCs derived cardiomyocytes |
Human iPSCs derived
cardiomyocytes |
N/A |
FPD and cardiac parameters |
Treatment with DHT:
FPD (equivalent to APD) shortening and hERG(G)
upregulation. |
LaFountaine et al. 2011 [38] |
Cross-sectional study: Testosterone
replacement therapy in males with hypogonadism and SCI (control:
eugonadal males with SCI) |
29 - 49 years old men with SCI |
34 |
ECG
parameters: APD, QTc and HR |
Treatment with testosterone: QT shortening
and K+ channels (IC) upregulation. |
Piccirillo et al. 2019 [39] |
Intervention study: Testosterone
replacement therapy in males with hypogonadism (control: eugonadal
males) |
35 - 70 years old men |
24 |
ECG parameters: QTe, QTp and Te |
Treatment with testosterone: QT shortening, IKs (IC)
upregulation and ICaL (IC) inhibition. |
Salem et al. 2018 [40] |
Prospective cohort study: Testosterone
replacement therapy in males with hypogonadism and/or taking ADT |
63 -
90 years old men |
7 |
Testosterone levels and LQT and TdP risk |
Treatment with testosterone: QTc shortening, IKr (IC)
upregulation, IKs (IC) upregulation,
ICaL (IC) inhibition. |
Salem et al. 2019 [41] |
Experimental study: ADT – Enzalutamide
(Xtandi®, Astellas Pharma US, Inc., Northbrook, IL) treatment in human
iPSC derived cardiomyocytes |
Human iPSC derived cardiomyocytes |
N/A |
ECG parameters: APD and HR; and effects of ADT |
Treatment with ADT: QT
prolongation, IKr (IC) inhibition acutely and
INaL (IC) upregulation chronically. |
Vicente et al. 2014 [42] |
Cross-sectional study: Testosterone
effects on ECG parameters |
21 - 72 years old men and women |
2235 |
ECG
parameters: QTc |
Presence of testosterone: QTc shortening,
IKs (IC) upregulation and ICaL (IC)
inhibition. |
Wu et al. 2008 [43] |
Experimental study: DHT treatment in HEK293
cells |
HEK293 cells transfected with hERG and either AR or AR45 |
N/A |
hERG expression and function |
Treatment with DHT: QT shortening and
hERG(G) upregulation. |